Is niraparib covered by medical insurance?

In December 2019, niraparib (Niraparib) was approved for marketing in China through the relevant regulations of the National Medical Products Administration. It is the first domestic innovative drug for ovarian cancer and the first Class 1 new drug PARP inhibitor. The generic drug name of niraparib is niraparib tosylate capsules, and the trade name is Zele. It has also been included in the Category B drug catalog, but reimbursement is limited to eligible patients, and patients who do not meet the conditions can only purchase it at their own expense.

Niraparib is an inhibitor of PARP enzymes (including PARP-1 and PARP-2), which plays a role in DNA repair. In vitro studies have shown that niraparibinduced cytotoxicity may involve the inhibition of PARP enzyme activity and the increase in the formation of PARP-DNA complexes, leading to DNA damage, apoptosis and cell death. Niraparib's medical insurance reimbursement conditions include maintenance treatment of adult patients with advanced epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer after achieving complete response or partial response to first-line platinum-containing chemotherapy; and maintenance treatment of adult patients with platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer after achieving complete response or partial response to platinum-containing chemotherapy.

The price of niraparib sold domestically Common specifications of the original drug100mg*30 capsules per box may be more than 5,000 yuan. The reimbursement ratio is different in different regions, and the price after reimbursement may be different. The original niraparib drug marketed overseas is more expensive than domestically. There are also generic niraparib drugs produced in other countries. Their pharmaceutical ingredients are basically the same as those of the original niraparib drug sold domestically and abroad. The price of 100mg*30 tablets per box produced by a Bangladesh pharmaceutical factory may be more than 1,000 yuan (the price may fluctuate due to exchange rates).